CClinicalTrials.gg
Sign In
CompletedNCT02929745Updated Sep 23, 2021

Single Cell Genomics of Psoriatic Skin

An interventional study of Skin biopsy and Blood draw in Psoriasis, sponsored by University of California, San Francisco. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-23.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to understand how genetics play a role in psoriasis. Specifically, a genetic allele HLA-Cw6 is known to be associated with psoriasis, and this study aims to find out how it affects genetic and protein expression in patients with psoriasis, compared to healthy people, at a single-cell level using a novel flow cytometry and RNA-sequencing protocol.

02

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • immunology, genetics
03

In context

Psoriasis

1,899 studies on the registry are indexed under Psoriasis; 233 are open to participants now.

This study's enrollment of 16 is below the median of 70 across 1,447 interventional studies indexed under Psoriasis.

Browse Psoriasis studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,132 studies on the registry; 375 are open to participants now.

Of its 262 completed or terminated interventional studies of FDA-regulated products, 196 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

For subjects in the psoriasis group:

  1. Ability to provide written consent and comply with the protocol
  2. At least 18 years of age
  3. Diagnosis of plaque psoriasis for at least 6 months prior to enrollment
  4. BSA > 5% and at least one target plaque on trunk or extremities greater than 10cm2

For control subjects:

  1. Ability to provide written consent and comply with the protocol
  2. At least 18 years of age
  3. No previous diagnosis of psoriasis or other inflammatory skin conditions

Exclusion criteria

Exclusion Criteria:

For subjects in the psoriasis group:

  1. Subject has non-plaque form of psoriasis.
  2. Subject has drug-induced psoriasis.
  3. Pregnancy at any point during the study period.
  4. Known allergy to lidocaine, other local anesthetics, or any component of local anesthetic agents.
  5. Known HIV positive status.
  6. Evidence of abnormality of any immune cell population from a drug-induced or genetic cause.
  7. Known coagulopathy.

For control subjects:

  1. Any physical examination findings by the investigators consistent with psoriasis or other inflammatory skin conditions.
  2. Pregnancy at any point during the study period.
  3. Known allergy to lidocaine, other local anesthetics, or any component of local anesthetic agents.
  4. Known HIV positive status.
  5. Evidence of abnormality of any immune cell population from a drug-induced or genetic cause.
  6. Known coagulopathy.
  7. Use of any immunosuppressant or immunomodulating therapies within 6 months.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    10 HLA-Cw6+

    HLA-Cw6+ patients will donate blood and skin samples

    Procedure: Skin biopsy · Procedure: Blood draw

  • Experimental
    10 HLA Cw6-

    HLA-Cw6- patients will donate blood and skin samples

    Procedure: Skin biopsy · Procedure: Blood draw

  • Experimental
    Healthy Skin

    Healthy patients will donate blood and skin samples

    Procedure: Skin biopsy · Procedure: Blood draw

Interventions

  • ProcedureSkin biopsy

    Four 4-5 mm punch biopsies of the skin

  • ProcedureBlood draw

    Blood will be drawn to test for HLA-cw6 status

06

What researchers measure

Primary outcomes

  1. Determination of immune cell population from skin biopsies

    Time frame: once

Secondary outcomes

  1. Determination of diferentially expressed genes from skin biopsies

    Time frame: once

  2. Determination of HLA -cw6 status from blood samples

    Time frame: once

07

Study locations

1 site
  • UCSF Psoriasis Center
    San Francisco, California 94118, United States
08

References and documents

Publications

  • Liu J, Chang HW, Huang ZM, Nakamura M, Sekhon S, Ahn R, Munoz-Sandoval P, Bhattarai S, Beck KM, Sanchez IM, Yang E, Pauli M, Arron ST, Fung-Leung WP, Munoz E, Liu X, Bhutani T, North J, Fourie AM, Rosenblum MD, Liao W. Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer. J Allergy Clin Immunol. 2021 Jun;147(6):2370-2380. doi: 10.1016/j.jaci.2020.11.028. Epub 2020 Dec 9. PubMed 33309739 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02929745
Lead sponsor
University of California, San Francisco
Collaborators
Janssen Pharmaceuticals
Responsible party
Sponsor
First posted
Oct 11, 2016
Start date
Jul 1, 2016
Primary completion
Dec 9, 2020
Completion
Dec 9, 2020
Last update
Sep 23, 2021

Study contacts

Wilson Liao, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Psoriasis→

Other studies from this sponsor

University of California, San Francisco

Start the discussion